Cancer chemotherapy and pharmacology
-
Cancer Chemother. Pharmacol. · Mar 2002
Clinical TrialPhase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
To investigate the safety and pharmacokinetics of a new liposomal formulation of cisplatin, SPI-77, in patients with advanced malignancies. ⋯ The results of this phase I trial show that the pharmacokinetic behaviour of cisplatin is significantly altered by its encapsulation in Stealth liposomes. The pharmacokinetics of SPI-77 are mainly dominated by the liposomal properties, resulting in high cholesterol concentrations and relatively low concentrations of (free) platinum in plasma, WBC and tumour tissue, which may explain the observed differences between the toxicity profiles of SPI-77 and cisplatin.